NCT07219407RecruitingPhase 2
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 8 Oct 2025
- Start date
- Dec 2025
- Primary completion date
- Feb 2028
- Lead sponsor
- Rapport Therapeutics Inc.
- Diseases
- Epilepsy
- NCT number
- NCT07219407
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From Dec 2025 to the primary completion date, Feb 2028
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known of hypersensitivity to RAP-219
Lab values
- Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator
Other
- Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods
Who the study is looking for
- Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.
- Diagnosis of refractory focal epilepsy
- Stable RNS(c) system settings
- A demonstrated history of compliance with RNS(c) system data interrogation and upload
- Good overall health other than focal epilepsy, per Investigator.
- BMI ≥ 18 kg/m\^2 and ≤ 45 kg/m\^2
- Willing and able to adhere to all aspects of the protocol.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Consultants in Epilepsy and Neurology PLLC Coordinator of this site? Confirm its status | Boise | United States | Recruiting |
| Cleveland Clinic Foundation Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
| Baylor College of Medicine Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
| NYU Langone Comprehensive Epilepsy Center Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| University of Pennsylvania - Department of Neurology Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.